Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Today's news is very good..
View:
Post by chry200030 on May 08, 2024 12:36pm

Today's news is very good..

Theralase hires two clinical research associates

Now we need news of BTD...
Comment by DeathXray33 on May 08, 2024 1:03pm
6. "Supporting Break Through Designation approval from the FDA in 3Q2024." ------------------------------------------------------------ That's starting in only Seven weeks.
Comment by gebremeskel on May 08, 2024 1:43pm
Yes, DeathXray33, that's starting in only seven weeks, but with all the good will in the world, Theralase's projected timeline for BTD submission cannot be trusted. It is now 16 months since the original date Theralase planned to submit the BTD application, which was December 2022. The estimated submission date has shifted forward numerous times. At this point no one can be blamed for ...more  
Comment by managementfirst on May 08, 2024 2:10pm
Yes BTD application timeline has been push forward 16 months, No one feel not annoying. But final line may be very near. There is no insdie buying in the last PP  may mean something.
Comment by BlueMetal75 on May 08, 2024 7:32pm
  You wish the deadline had been brought forward. What you actually meant is that its been pushed BACK, several times.
Comment by Oilminerdeluxe on May 09, 2024 6:03am
Hopefully, the next update can bring some light to things. If they are waiting for information they have no control over, the wait can be eternal. Buraucracy is what it is.
Comment by Alamir1111 on May 08, 2024 2:36pm
Supporting Break Through Designation approval from the FDA in 3Q2024. No mention of pre Btd was it granted ???
Comment by toade1313 on May 08, 2024 4:43pm
Company won't even say if pre BTD was filed yet.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250